TYRA
NASDAQ HealthcareTyra Biosciences, Inc. - Common Stock
Biotechnology
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
�� 市场数据
| 价格 | $35.56 |
|---|---|
| 成交量 | 1,336,957 |
| 市值 | 1.92B |
| 贝塔系数 | 0.960 |
| RSI（14日） | 47.1 |
| 200日均线 | $21.55 |
| 50日均线 | $34.64 |
| 52周最高 | $40.65 |
| 52周最低 | $7.80 |
| Forward P/E | -13.86 |
| Price / Book | 7.37 |
🎯 投资策略评分
TYRA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (76/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🎈 Over-Hyped (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TYRA in your text
粘贴任何文章、记录或帖子 — 工具将提取 TYRA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.